[go: up one dir, main page]

WO2003068753A1 - N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient - Google Patents

N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient Download PDF

Info

Publication number
WO2003068753A1
WO2003068753A1 PCT/JP2003/001481 JP0301481W WO03068753A1 WO 2003068753 A1 WO2003068753 A1 WO 2003068753A1 JP 0301481 W JP0301481 W JP 0301481W WO 03068753 A1 WO03068753 A1 WO 03068753A1
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
active ingredient
fused ring
drugs
carbamoyl nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/001481
Other languages
English (en)
French (fr)
Inventor
Takuya Seko
Seishi Katsumata
Masashi Kato
Jun-Ichiro Manako
Kazuyuki Ohmoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to US10/504,422 priority Critical patent/US7368444B2/en
Priority to AU2003211951A priority patent/AU2003211951A1/en
Priority to EP03705105A priority patent/EP1475368A4/en
Priority to JP2003567884A priority patent/JPWO2003068753A1/ja
Publication of WO2003068753A1 publication Critical patent/WO2003068753A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2003/001481 2002-02-14 2003-02-13 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient Ceased WO2003068753A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/504,422 US7368444B2 (en) 2002-02-14 2003-02-13 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient
AU2003211951A AU2003211951A1 (en) 2002-02-14 2003-02-13 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient
EP03705105A EP1475368A4 (en) 2002-02-14 2003-02-13 FUSED CORE COMPOUNDS CONTAINING N-CARBAMOYL NITROGEN AND MEDICAMENTS CONTAINING SAID COMPOUNDS AS ACTIVE INGREDIENTS
JP2003567884A JPWO2003068753A1 (ja) 2002-02-14 2003-02-13 Ｎ−カルバモイル窒素含有縮合環化合物およびその化合物を有効成分として含有する薬剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002036340 2002-02-14
JP2002-36340 2002-02-14

Publications (1)

Publication Number Publication Date
WO2003068753A1 true WO2003068753A1 (en) 2003-08-21

Family

ID=27678082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/001481 Ceased WO2003068753A1 (en) 2002-02-14 2003-02-13 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient

Country Status (6)

Country Link
US (1) US7368444B2 (ja)
EP (1) EP1475368A4 (ja)
JP (1) JPWO2003068753A1 (ja)
AU (1) AU2003211951A1 (ja)
TW (1) TW200305423A (ja)
WO (1) WO2003068753A1 (ja)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113300A1 (ja) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
WO2005040135A1 (ja) * 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. 抗ストレス薬およびその医薬用途
WO2005047286A1 (ja) * 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
WO2005063241A1 (ja) * 2003-12-26 2005-07-14 Ono Pharmaceutical Co., Ltd. ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
FR2867187A1 (fr) * 2004-03-02 2005-09-09 Centre Nat Rech Scient Procede utile pour la preparation de benzazepines et derives de celles-ci.
WO2006044707A1 (en) * 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
EP2011481A2 (fr) 2007-07-06 2009-01-07 L'Oreal Composition de protection solaire contenant l'association d'un polymère semi-cristallin et de particules de latex creuses
EP2014277A1 (fr) 2007-07-12 2009-01-14 L'Oreal Composition photoprotectrice fluide aqueuse à base d'un polymère polyamide à terminaison amide tertiaire
EP2016932A2 (fr) 2007-07-09 2009-01-21 L'Oréal Utilisation pour la coloration de la peau de l'acide dehydroascorbique ou de ses derives polymeres ; procedes de soin et/ou de maquillage
EP2119429A1 (fr) 2008-05-14 2009-11-18 L'Oréal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone ; procede de photostabilisation du derive de dibenzoylmethane
EP2174644A1 (fr) 2008-10-08 2010-04-14 L'oreal Composition cosmétique contenant un dérivé de dibenzoylméthane et un composé dithiolane; procédé de photostabilisation du dérivé de dibenzoylmethane
EP2191869A1 (fr) 2008-12-01 2010-06-02 L'oreal Procédé de coloration artificielle de la peau utilisant un mélange de caroténoide et de colorant vert lipophile ; nouveau mélange de colorants lipophiles ; composition
US7741317B2 (en) * 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7964726B2 (en) 2004-12-22 2011-06-21 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
WO2011073279A2 (fr) 2009-12-18 2011-06-23 L'oreal Procédé de traitement cosmétique impliquant un composé apte à condenser in situ
WO2011151203A2 (en) 2010-06-03 2011-12-08 L'oreal Cosmetic treatment process using a coating based on a copolymer containing polyamide blocks and polyether blocks
CN103804367A (zh) * 2014-02-28 2014-05-21 天津药物研究院 苯并氮杂卓衍生物、其制备方法和用途
JP2014534261A (ja) * 2011-11-21 2014-12-18 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ カルボキシｘローダミン類似体
US9266883B2 (en) 2013-10-25 2016-02-23 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006067327A2 (fr) * 2004-12-20 2006-06-29 L'oreal Antagonistes des recepteurs peripheriques des benzodiazepines pour le traitement des peaux seches
BRPI0517216A (pt) * 2004-12-20 2008-09-30 Oreal uso cosmético de pelo menos um antagonista dos receptores periféricos das benzodizepinas e processo cosmético para combater as rugas ou as rìdulas
KR100651849B1 (ko) * 2005-02-01 2006-12-01 엘지전자 주식회사 세탁기
JP5188988B2 (ja) * 2006-02-10 2013-04-24 トランステック ファーマ，インコーポレイティド ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法
US20070208001A1 (en) * 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2008141082A1 (en) * 2007-05-10 2008-11-20 Amr Technology, Inc. Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
HRP20170617T1 (hr) 2010-07-14 2017-06-30 Novartis Ag Heterociklički spojevi kao agonisti ip-receptora
UY34572A (es) 2012-01-13 2013-09-02 Novartis Ag Compuestos heterocíclicos agonistas del receptor ip
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10683283B2 (en) 2016-09-01 2020-06-16 Mebias Discovery, Inc. Substituted ureas and methods of making and using same
CA3050515A1 (en) 2017-01-17 2018-07-26 Mebias Discovery, Inc. Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
JP2025506410A (ja) * 2022-02-03 2025-03-11 シーフォーエックス・ディスカバリー・リミテッド Ｍａｌｔ１阻害剤としてのヘテロ環誘導体
CN115246842B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类靶向去泛素化酶usp25和usp28的小分子抑制剂
CN117088814A (zh) * 2023-02-16 2023-11-21 烟台大学 一种三氟甲硫化氮杂-8/9元环化合物的制备方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US378321A (en) * 1888-02-21 Rankin kennedy
FR1473839A (fr) * 1965-04-02 1967-03-24 Alphachimie Nouveaux dérivés de la 2, 3, 4, 5-tétrahydro-(1h)-1-benzazépine et leurs procédés de fabrication
US3346565A (en) * 1963-05-22 1967-10-10 Lepetit Spa 1, 2, 3, 5-tetrahydro-4, 1-benzoxazepines and 3, 5-dehydro-4, 1-benzoxazepin-2-(1h)-ones
US3395150A (en) * 1965-02-26 1968-07-30 Squibb & Sons Inc Benzothiazepine carboxamides and derivatives thereof
US3458498A (en) * 1966-04-25 1969-07-29 American Home Prod Certain 1-acyl derivatives of 7-alkoxy-2,3,4,5-tetrahydro-1h-1-benzazepine
GB1193534A (en) * 1968-02-12 1970-06-03 Ucb Sa Novel Benzazocine Derivatives, the Preparation thereof and Compositions Containing the same
US3516987A (en) * 1966-04-25 1970-06-23 American Home Prod 1-methylsulfonyl-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine
US3542760A (en) * 1966-04-25 1970-11-24 American Home Prod 7-alkoxy-2,3,4,5-tetrahydro-1h-1-benzazepine and derivatives thereof
US3960876A (en) * 1974-03-05 1976-06-01 John Wyeth & Brother, Ltd. Certain 1-carbothioamides of 1,8-naphthyridines, pyrrolo(2,3-b)pyridines and pyrido(2,3-b)azepines
US4029667A (en) * 1974-03-05 1977-06-14 John Wyeth & Brother Limited Certain 1-carbothioamides of 1,8-naphthyridines, pyrrolo(2,3-b)pyridines and pyrido(2,3-b)azepines
WO2001032610A1 (en) * 1999-10-29 2001-05-10 Kaken Pharmaceutical Co., Ltd. Urea derivative, process for producing the same, and medicine containing the urea derivative
WO2003030937A1 (en) * 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US378321A (en) * 1888-02-21 Rankin kennedy
US3346565A (en) * 1963-05-22 1967-10-10 Lepetit Spa 1, 2, 3, 5-tetrahydro-4, 1-benzoxazepines and 3, 5-dehydro-4, 1-benzoxazepin-2-(1h)-ones
US3395150A (en) * 1965-02-26 1968-07-30 Squibb & Sons Inc Benzothiazepine carboxamides and derivatives thereof
FR1473839A (fr) * 1965-04-02 1967-03-24 Alphachimie Nouveaux dérivés de la 2, 3, 4, 5-tétrahydro-(1h)-1-benzazépine et leurs procédés de fabrication
US3458498A (en) * 1966-04-25 1969-07-29 American Home Prod Certain 1-acyl derivatives of 7-alkoxy-2,3,4,5-tetrahydro-1h-1-benzazepine
US3516987A (en) * 1966-04-25 1970-06-23 American Home Prod 1-methylsulfonyl-7-methoxy-2,3,4,5-tetrahydro-1h-1-benzazepine
US3542760A (en) * 1966-04-25 1970-11-24 American Home Prod 7-alkoxy-2,3,4,5-tetrahydro-1h-1-benzazepine and derivatives thereof
GB1193534A (en) * 1968-02-12 1970-06-03 Ucb Sa Novel Benzazocine Derivatives, the Preparation thereof and Compositions Containing the same
US3960876A (en) * 1974-03-05 1976-06-01 John Wyeth & Brother, Ltd. Certain 1-carbothioamides of 1,8-naphthyridines, pyrrolo(2,3-b)pyridines and pyrido(2,3-b)azepines
US4029667A (en) * 1974-03-05 1977-06-14 John Wyeth & Brother Limited Certain 1-carbothioamides of 1,8-naphthyridines, pyrrolo(2,3-b)pyridines and pyrido(2,3-b)azepines
WO2001032610A1 (en) * 1999-10-29 2001-05-10 Kaken Pharmaceutical Co., Ltd. Urea derivative, process for producing the same, and medicine containing the urea derivative
WO2003030937A1 (en) * 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BEATTIE, DOREEN E. ET AL.: "5,6,7,8-Tetrahydroquinolines. 5. Antiulcer and antisecretory activity of 5,6,7,8-tetrahydroquinolinethioureas and related heterocycles", JOURNAL OF MEDICINAL CHEMISTRY, vol. 20, no. 5, 1977, pages 718 - 721, XP002969401 *
DODD ROBERT H. ET AL.: "Modification of mitochondrial benzodiazepine receptor numbers in stressful situations", PERIPHER. BENZODIAZEPINE RECEPT, 1993, pages 187 - 207, XP002969403 *
ISHIHARA YUJI ET AL.: "Regioselective Friedel-Crafts acylation of 1,2,3,4-tetrahydroquinoline and related nitrogen heterocycles: effects of NH protective groups and ring size", J. CHEM. SOC. PERKIN TRANS. 1, vol. 24, 1992, pages 3401 - 3406, XP002968898 *
KHANNA J.M. ET AL.: "Agents acting on the central nervous system. X. 1-Substituted 3-phenyl-2,3,4,5-tetrahydro-1H-1benzazepines", JOURNAL OF MEDICINAL CHEMISTRY, vol. 395, no. 10, 1967, pages 944 - 945, XP002968897 *
TESTA E. ET AL.: "Substances active on the nervous system. XXXVIII. Synthesis of 5-phenyl-3,5-dihydro-4,1-benzoazepin-2(1H)-ones and 5-phenyl.2.3.5-tetrahydro-4,1-benzoxazepines", FARMACO(PAVIA), ED. SCI., vol. 18, no. 11, 1963, pages 815 - 827, XP002969402 *
YANAGIDA A. JOSSANG ET AL.: "Derivatives of 2,3,4,5-tetrahydro-1H-pyrido(3,2-b)azepine, of 2,3,4,5-tetrahydro-1H-pyrido(2,3-b)azepine and their corresponding lactams. II. Synthesis and pharmacological study on their psychotropic activity", FARMACO, EDIZIONE SCIENTIFICA, vol. 34, no. 1, 1979, pages 26 - 35 *
YANAGIDA A. JOSSANG ET AL.: "Derivatives of tetrahydropyrido azepines and tetrahydropyridoazepinones. I. Derivatives of 2,3,4,5-tetrahydro-1H-pyrido(3,2-b)azepine and the corresponding lactam", FARMACO, EDIZIONE SCIENTIFICA, vol. 33, no. 12, 1978, pages 984 - 991, XP002968899 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113300A1 (ja) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
US7872133B2 (en) 2003-06-23 2011-01-18 Ono Pharmaceutical Co., Ltd. Tricyclic heterocycle compound
WO2005040135A1 (ja) * 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. 抗ストレス薬およびその医薬用途
WO2005047286A1 (ja) * 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
WO2005063241A1 (ja) * 2003-12-26 2005-07-14 Ono Pharmaceutical Co., Ltd. ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
FR2867187A1 (fr) * 2004-03-02 2005-09-09 Centre Nat Rech Scient Procede utile pour la preparation de benzazepines et derives de celles-ci.
WO2006044707A1 (en) * 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
US8952158B2 (en) 2004-12-22 2015-02-10 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
US8476293B2 (en) 2004-12-22 2013-07-02 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
US7964726B2 (en) 2004-12-22 2011-06-21 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
US7741317B2 (en) * 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2011481A2 (fr) 2007-07-06 2009-01-07 L'Oreal Composition de protection solaire contenant l'association d'un polymère semi-cristallin et de particules de latex creuses
EP2016932A2 (fr) 2007-07-09 2009-01-21 L'Oréal Utilisation pour la coloration de la peau de l'acide dehydroascorbique ou de ses derives polymeres ; procedes de soin et/ou de maquillage
EP2014277A1 (fr) 2007-07-12 2009-01-14 L'Oreal Composition photoprotectrice fluide aqueuse à base d'un polymère polyamide à terminaison amide tertiaire
EP2119429A1 (fr) 2008-05-14 2009-11-18 L'Oréal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone ; procede de photostabilisation du derive de dibenzoylmethane
EP2174644A1 (fr) 2008-10-08 2010-04-14 L'oreal Composition cosmétique contenant un dérivé de dibenzoylméthane et un composé dithiolane; procédé de photostabilisation du dérivé de dibenzoylmethane
EP2191869A1 (fr) 2008-12-01 2010-06-02 L'oreal Procédé de coloration artificielle de la peau utilisant un mélange de caroténoide et de colorant vert lipophile ; nouveau mélange de colorants lipophiles ; composition
WO2011073279A2 (fr) 2009-12-18 2011-06-23 L'oreal Procédé de traitement cosmétique impliquant un composé apte à condenser in situ
WO2011073280A2 (fr) 2009-12-18 2011-06-23 L'oreal Procédé de traitement cosmétique impliquant un composé apte à condenser in situ résistant
WO2011151203A2 (en) 2010-06-03 2011-12-08 L'oreal Cosmetic treatment process using a coating based on a copolymer containing polyamide blocks and polyether blocks
JP2014534261A (ja) * 2011-11-21 2014-12-18 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ カルボキシｘローダミン類似体
US9533988B2 (en) 2013-10-25 2017-01-03 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US9266883B2 (en) 2013-10-25 2016-02-23 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US9896449B2 (en) 2013-10-25 2018-02-20 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
CN103804367A (zh) * 2014-02-28 2014-05-21 天津药物研究院 苯并氮杂卓衍生物、其制备方法和用途
CN103804367B (zh) * 2014-02-28 2016-09-14 天津药物研究院 苯并氮杂卓衍生物、其制备方法和用途
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide

Also Published As

Publication number Publication date
US20050101600A1 (en) 2005-05-12
TW200305423A (en) 2003-11-01
EP1475368A4 (en) 2006-03-29
EP1475368A1 (en) 2004-11-10
US7368444B2 (en) 2008-05-06
AU2003211951A1 (en) 2003-09-04
JPWO2003068753A1 (ja) 2005-06-02

Similar Documents

Publication Publication Date Title
WO2003068753A1 (en) N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient
WO2003030937A1 (en) Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
WO2003087094A3 (en) Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
WO2002010135A1 (en) 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
WO2005046603A3 (en) Pyridine compounds
WO2003084943A3 (fr) Derives de terphenyle, leur preparation, les compositions pharmaceutiques en contenant
AU2002350961A1 (en) Ethylene diamine derivatives and their use as orexin-receptor antagonists
WO2003000699A8 (de) Substituierte 1-oxa-2,8-diaza-spiro[4,5]dec-2-en-derivate als arzneimittel gegen schmerz
AU2003270199A1 (en) Urea compounds active as vanilloid receptor antagonists for the treatment of pain
WO2004073619A3 (en) Ccr8 antagonists
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
AU2003239389A1 (en) Opioid receptor antagonists
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
WO2000075107A3 (en) Bradykinin receptor antagonists
AP1766A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation.
WO2005035537A3 (en) Substituted tricyclic heterocycles and their uses
WO2005117895A8 (en) Compositions comprising meloxicam
WO2003037863A3 (de) Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003567884

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003705105

Country of ref document: EP

Ref document number: 10504422

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003705105

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003705105

Country of ref document: EP